Stocks and Investing Stocks and Investing
Tue, July 21, 2020

Gregory Renza Maintained (ACAD) at Buy with Decreased Target to $55 on, Jul 21st, 2020


Published on 2024-10-27 10:03:12 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $61 to $55 on, Jul 21st, 2020.

Gregory has made no other calls on ACAD in the last 4 months.



There are 3 other peers that have a rating on ACAD. Out of the 3 peers that are also analyzing ACAD, 0 agree with Gregory's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Gregory


  • Paul Matteis of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $71 on, Tuesday, July 7th, 2020
  • Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $60 on, Thursday, April 16th, 2020
  • Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $72 on, Tuesday, March 31st, 2020

Contributing Sources